Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Firstsource Solutions Q2 FY26 Earnings Results
Firstsource Solutions Ltd, a leading player in Business Process Management (BPM) and part of the…
-
Foseco India Q2 FY26 Earnings Results
Foseco India Ltd, incorporated in 1958 and engaged in manufacturing metallurgical additives and consumables that…
-
Force Motors Q2 FY26 Earnings Results
Force Motors Ltd, founded in 1958 and part of the Abhay Firodia Group, specializes in…